Michaeli, Daniel Tobias

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 109

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 23

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 20

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthHealth Systems, Economic Evaluations, Quality of Life

Cited by 9

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · European Heart Journal

Health Systems, Economic Evaluations, Quality of LifeFatty Acid Research and Health

Cited by 1